Literature DB >> 31175094

A Novel Oxoglutarate Dehydrogenase-Like Mediated miR-214/TWIST1 Negative Feedback Loop Inhibits Pancreatic Cancer Growth and Metastasis.

Fanzheng Meng1, Mingyang Liu2, Guangchao Yang1, Jizhou Wang1, Yufeng Liu1, Yao Liu1,2, Jiabei Wang1, Ruipeng Song1, Tongsen Zheng3, Yingjian Liang1, Shugeng Zhang1, Dalong Yin1, Haiyan Yang1, Shangha Pan4, Bo Sun5, Jihua Han1, Jing Sun1, Yaliang Lan1, Yan Wang1, Xirui Liu1, Mingxi Zhu1, Yifeng Cui1, Bo Zhang1, Dehai Wu1, Shuhang Liang1, Xuan Song1, Zhaoyang Lu1, Jingxuan Yang2, Min Li6, Lianxin Liu7.   

Abstract

PURPOSE: As a main rate-limiting subunit of the 2-oxoglutarate dehydrogenase multienzyme complex, oxoglutarate dehydrogenase like (OGDHL) is involved in the tricarboxylic acid cycle, and frequently downregulated in human carcinoma and suppresses tumor growth. However, little is known about the role of OGDHL in human cancer, especially pancreatic cancer. Our goal is to study the underlying mechanism and define a novel signaling pathway controlled by OGDHL modulating pancreatic cancer progression. EXPERIMENTAL
DESIGN: The expression and functional analysis of OGDHL, miR-214, and TWIST1 in human pancreatic cancer tissues, cell lines, and xenograft tumor model were investigated. The correlations between OGDHL and those markers were analyzed.
RESULTS: OGDHL was downregulated in human pancreatic cancer and predicted poor prognosis. OGDHL overexpression inhibited migration and invasion of pancreatic cancer cells and suppressed pancreatic cancer tumor growth. OGDHL was shown to be negatively regulated by miR-214. TWIST1 upregulation induced miR-214 expression in pancreatic cancer. OGDHL suppressed TWIST1 expression through promoting ubiquitin-mediated proteasomal degradation of HIF1α and regulating AKT pathways. A combination of OGDHL downregulation and TWIST1 and miR-214 overexpression predicted worse prognosis in patients with pancreatic cancer.
CONCLUSIONS: We demonstrated the prognostic value of OGDHL, miR-214, and TWIST1 in pancreatic cancer, and elucidated a novel pathway in OGDHL-regulated inhibition of pancreatic cancer tumorigenesis and metastasis. These findings may lead to new targeted therapy for pancreatic cancer through regulating OGDHL, miR-214, and TWIST1. ©2019 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31175094     DOI: 10.1158/1078-0432.CCR-18-4113

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  5 in total

Review 1.  Targeting 2-oxoglutarate dehydrogenase for cancer treatment.

Authors:  Ling-Chu Chang; Shih-Kai Chiang; Shuen-Ei Chen; Mien-Chie Hung
Journal:  Am J Cancer Res       Date:  2022-04-15       Impact factor: 5.942

2.  B7-H3 is eligible for predicting clinical outcomes in lung adenocarcinoma patients treated with EGFR tyrosine kinase inhibitors.

Authors:  Ying Yang; Jun-Feng Huang; Bing-Qi Hu; Jing Zhou; Xian Wang; Zhen-Zhong Feng; Yu-Ting Chen; Fa-Ming Pan; Huai-Dong Cheng; Li-Wen Chen
Journal:  World J Surg Oncol       Date:  2022-05-20       Impact factor: 3.253

Review 3.  The Role of Feedback Loops in Targeted Therapy for Pancreatic Cancer.

Authors:  Weigang Gu; HongZhang Shen; Lu Xie; Xiaofeng Zhang; Jianfeng Yang
Journal:  Front Oncol       Date:  2022-05-16       Impact factor: 5.738

4.  OGDHL closely associates with tumor microenvironment and can serve as a prognostic biomarker for papillary thyroid cancer.

Authors:  Min Mao; Rong-Zhi Huang; Jie Zheng; Hai-Qi Liang; Wen-Hui Huang; Jing Liu; Jie-Hua Li
Journal:  Cancer Med       Date:  2021-01-06       Impact factor: 4.452

5.  A novel mitochondrial amidoxime reducing component 2 is a favorable indicator of cancer and suppresses the progression of hepatocellular carcinoma by regulating the expression of p27.

Authors:  Dehai Wu; Yan Wang; Guangchao Yang; Shugeng Zhang; Yao Liu; Shuo Zhou; Hongrui Guo; Shuhang Liang; Yifeng Cui; Bo Zhang; Kun Ma; Congyi Zhang; Yufeng Liu; Linmao Sun; Jiabei Wang; Lianxin Liu
Journal:  Oncogene       Date:  2020-08-18       Impact factor: 9.867

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.